Barcode technology could help diagnose cancer more precisely

William Oh named service medical director at Smilow Cancer Hospital at Greenwich

William K. Oh was appointed as service medical director of Smilow Cancer Hospital at Greenwich Hospital, as well as director of precision medicine for Yale Cancer Center and Smilow Cancer Hospital.

November 22, 2024

Vol.50 No.44

In Brief

Victor Ambros and Gary Ruvkun share 2024 Nobel Prize in Physiology or Medicine

Victor AmbrosPhoto credit: Niklas Elmehed © Nobel Prize OutreachGary RuvkunPhoto credit: Niklas Elmehed © Nobel Prize OutreachVictor Ambros and Gary Ruvkun were jointly awarded the 2024 Nobel Prize in Physiology or Medicine from the Nobel Assembly at the Karolinska Institutet. The two scientists are being honored for their discovery of microRNA and its role in post-transcriptional gene regulation.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Noncoding RNA molecule plays surprising role in senescence

A team led by UT Southwestern Medical Center researchers has discovered a new way that cells regulate senescence, an irreversible end to cell division.

July 19, 2024

Vol.50 No.29

Cancer History Project Guest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

In the Archives

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.

July 05, 2024

Vol.50 No.27

Drugs & Targets

Secarna, Orbit collaborate to develop peptide-conjugated targeted ASO therapeutics

Secarna Pharmaceuticals GmbH & Co. KG, an independent European antisense drug discovery and development company, and Orbit Discovery Ltd., a leader in the discovery of therapeutic peptide hits, announced a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics.

May 31, 2024

Vol.50 No.22

Barcode technology could help diagnose cancer more precisely

YOU MAY BE INTERESTED IN

William Oh named service medical director at Smilow Cancer Hospital at Greenwich

Victor Ambros and Gary Ruvkun share 2024 Nobel Prize in Physiology or Medicine

Noncoding RNA molecule plays surprising role in senescence

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Secarna, Orbit collaborate to develop peptide-conjugated targeted ASO therapeutics

Renew today!

Subscriber content

Never miss an issue!

Login